Sign In
Buy KVUE
$19.24
-0.0700 (-0.363%)
At Close: Jul 31, 2026
Dividend Investors in This Unique Stock-Split Stock Have a Decision to Make
07:30am, Tuesday, 25'th Jul 2023
Johnson & Johnson is splitting off its consumer healthcare business to shareholders. They can exchange all, some, or none of their shares for Kenvue stock.
Johnson & Johnson Offers Exchange for Shares of Spinoff Kenvue
11:30am, Monday, 24'th Jul 2023
Johnson & Johnson offers its shareholders the choice to exchange its shares for Kenvue's, the consumer health company it spun off just two months ago.
Johnson & Johnson to reduce its Kenvue stake by at least 80% through exchange offer
09:03am, Monday, 24'th Jul 2023
J&J said it received a waiver that dismisses the share lockup period associated with Kenvue's initial public offering in May.
Johnson & Johnson launches share exchange offering for Kenvue
08:54am, Monday, 24'th Jul 2023
Johnson & Johnson (NYSE:JNJ) (J&J) has launched a share exchange offer for its former consumer health business Kenvue which completed its initial public offering in May. Shareholders of J&J can opt to
J&J begins share exchange offer for consumer health spin-off Kenvue
06:38am, Monday, 24'th Jul 2023
Johnson & Johnson said on Monday it had launched an exchange offer for its investors to exchange J&J's shares with those of its consumer health unit Kenvue.
Johnson & Johnson to spin off at least 80.1% of Kenvue shares in an exchange offer
06:29am, Monday, 24'th Jul 2023
Johnson & Johnson JNJ, +1.07% said Monday it is planning to spin off at least 80.1% of its shares of Kenvue Inc. KVUE, -2.04% through an exchange offer. The consumer goods and healthcare giant announc
Kenvue CEO says consumers are spending on brand-name health products even as they pull back in other areas
04:47pm, Friday, 21'st Jul 2023
Thibaut Mongon's remarks follow Kenvue's second-quarter earnings beat, which was fueled by resilient demand for brands like Band-Aid, Tylenol and Aveeno.
Kenvue CEO talks earnings, strong demand, stock: 'We are focused on the power of our portfolio'
04:15pm, Thursday, 20'th Jul 2023
Yahoo Finance health care reporter Anjalee Khemlani spoke with Kenvue CEO Thibaut Mongon about the company's latest earnings report, the outlook for growth, product portfolio, and Johnson & Johnson.
Johnson & Johnson investors can soon swap their shares for Kenvue stock — here's what you need to know
03:44pm, Thursday, 20'th Jul 2023
J&J owns nearly 90% of Kenvue shares and plans to reduce its stake in the company through an exchange offer that could launch "as early as the coming days."
Is Johnson & Johnson Giving Up on Kenvue (KVUE) Stock?
02:36pm, Thursday, 20'th Jul 2023
One of the more interesting moves in today's market comes from recent spinoff Kenvue (NYSE: KVUE ). Currently, shares of KVUE stock are down around 3% in today's session, as the company reported ear
Johnson & Johnson Rips Off the Kenvue Band-Aid
12:06pm, Thursday, 20'th Jul 2023
A surprisingly early distribution and a stretched valuation hit J&J's consumer health arm hard.
Stock movers July 20, 2022: Johnson & Johnson, Kenvue, and Abbott Labs
11:38am, Thursday, 20'th Jul 2023
Johnson & Johnson, Kenvue, and Abbott Labs posted second quarter results that topped analyst estimates. Yahoo Finance Live anchors break down the market reaction to the report.
J&J spinoff Kenvue CEO on first full quarterly earnings results since IPO
11:34am, Thursday, 20'th Jul 2023
Thibaut Mongon, Kenvue CEO, joins 'Squawk on the Street' to discuss the company's quarterly earnings results, what Mongon is seeing from the consumer, and much more.
Kenvue earnings top estimates in J&J spinoff's first quarterly report since IPO
07:32am, Thursday, 20'th Jul 2023
J&J still owns a 90% stake in Kenvue, meaning it can generally control the direction of the consumer health spinoff's business for the time being.
Tylenol, Benadryl parent Kenvue tops earnings expectations, amid strength in pain care, cold and flu product demand
06:32am, Thursday, 20'th Jul 2023
Tylenol, Benadryl and Listerine brands parent Kenvue Inc. KVUE, +0.77% reported Thursday second-quarter profit and revenue that beat expectations, provided an upbeat full-year outlook and initiated a
